|
Synonyms: Ilumetri® | Ilumya® | MK-3222 | MK3222 | SCH-900222 | SCH900222 | SUNPG1623 | tildrakizumab-asmn
tildrakizumab is an approved drug (EMA & FDA (2018))
Compound class:
Antibody
|
| No information available. |
Summary of Clinical Use ![]() |
| Tildrakizumab completed Phase 3 clinical trial for plaque psoriasis (NCT01729754 and NCT01722331), and having shown significant clinical benefit over placebo and etanercept and a favourable safety profile [3], was EMA and FDA approved in 2018, for the treatment of phototherapy candidate, adult patients with moderate to severe plaque psoriasis. In October 2026, the FDA expanded tildrakizumab's approval to include treatment of active psoriatic arthritis. |
External links ![]() |
|
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |